The ZDHHC7 inhibitor S-(2-acetamidoethyl) 2-bromohexadecanethioate (MY-D-4) has been shown to effectively suppress HCC growth, suggesting that ZDHHC7 could be a novel molecular marker of HCC. Here, ZDHHC7 is linked to hepatocellular carcinoma.